Prescribers and drug withdrawals

  title={Prescribers and drug withdrawals},
  author={Gillian M. Shenfield},
  journal={Australian Prescriber},
  • G. Shenfield
  • Published 1 June 2005
  • Medicine
  • Australian Prescriber
The much publicised withdrawal of rofecoxib and the subsequent queries about the safety of celecoxib evoked a huge response in both the lay and the medical press. 
1 Citations
Irrational drug combinations: Need to sensitize undergraduates
The basis of many fixed dose drug combinations being taught to the undergraduate medical students and also being prescribed popularly, appears to be irrational to pharmacologists.


Drug withdrawals from the Canadian market for safety reasons, 1963–2004
  • J. Lexchin
  • Medicine
    Canadian Medical Association Journal
  • 2005
By studying drugs that have been withdrawn from the market for safety reasons, we can gain valuable insight into postmarketing surveillance as well as the process for approving new drugs. In the past
Lessons from early large‐scale adoption of celecoxib and rofecoxib by Australian general practitioners
It is argued that hard work and a resolute focus on unravelling the unknown in medicine were rewarded with living to an advanced age, and paragons of this phenomenon included Virchow, the famed pathologist, Harvey, discoverer of the circulation, and the French surgeon Ambroise Paré.
How to make the most of a visit from a pharmaceutical company representative
A visit from a pharmaceutical company representative is an opportunity for the health professional to obtain important information about the drugs available in the market.
Treatment of Tobacco Use and Dependence
A 66-year-old woman with stable angina and a history of depression smokes 25 cigarettes daily. She would like to stop smoking but is concerned about weight gain. She has made several unsuccessful
COX-1-sparing NSAIDs--is the enthusiasm justified?
A recent comparison of gastric COX inhibition in healthy humans indicates that rofecoxib and celecoxib spare gastricCOX-1 to a much greater extent and the relative COX-2 selectivity of NSAIDs has been assessed most commonly.
A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants.
Treatment with poractant alfa resulted in rapid reduction in supplemental oxygen with fewer additional doses of surfactant versus treatment with beractant in infants <35 weeks gestation with RDS, and significantly reduced mortality.
Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.
The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours after start of treatment, associated with a trend towards reduced incidence of serious pulmonary and non-pulmonary complications.
Current pharmacological treatments for nicotine dependence.
Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf.
Meta-analysis of three prophylaxis versus rescue treatment trials conducted in four countries shows that for the porcine surfactant Curosurf, Prophylactic administration of surfactants has significant advantages over rescue therapy.
Mortality in relation to smoking: 50 years' observations on male British doctors
A substantial progressive decrease in the mortality rates among non-smokers over the past half century has been wholly outweighed, among cigarette smokers, by a progressive increase in the smoker νNon-smoker death rate ratio due to earlier and more intensive use of cigarettes.